In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Importance The high cost of biologics used to treat cancer has been an increasing burden in
the world. In China, the recent approval of cancer biosimilar drugs to resolve this problem is …

Nanoparticle polymeric micellar paclitaxel (Pm-Pac) has been demonstrated to have a
safety profile and efficacy in advanced non-small cell lung cancer (NSCLC) patients …

Background Nanocarrier platforms have been indicated to have great potential in clinical
practice to treat non-small cell lung cancer (NSCLC). Our previous Phase III clinical study …

Background Bevacizumab has played an important role in the systemic treatment of patients
with advanced non-small-cell lung cancer (NSCLC) without gene mutation. In recent years …

Introduction: The role of bevacizumab combined with paclitaxel and carboplatin in the first-
line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) has been …

Atezolizumab, an immune checkpoint inhibitor, has been approved for use in clinical
practice in non-small cell lung cancer (NSCLC) patients, but potential biomarkers for …

Immunotherapy, a chemotherapy-free process, has emerged as a promising therapeutic
strategy to prolong the overall survival (OS) of patients with non-small-cell lung cancer …

Biosimilars play an important role in reducing the burden on patients and increasing the
market competition. Biosimilar monoclonal antibodies are currently one of the hotspots of …

Objective Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies are an
effective means of treating non-small cell lung cancer (NSCLC). Here, we aim to update the …